Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07729605) titled 'FOLFIRI Plus Bevacizuamb and QL1706 in Second-Line Treatment for mCRC' on July 22.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Sun Yat-sen University
Condition:
Colorectal Cancer Metastatic
Microsatellite Stable (MSS) Colorectal Cancer (CRC)
Intervention:
Drug: FOLFIRI + bevacizumab + QL1706
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: July 30, 2026
Target Sample Size: 270
Countries of Recruitment:
China
To know more, visit https://clinica...